Latest Headlines

Latest Headlines

Jimenez counts on 7 drugs to take Novartis past Diovan

Maybe it's the rarefied Davos air or the long-range mountain views, but Novartis ($NVS) CEO Joe Jimenez is feeling optimistic about the post- Diovan future. After the Swiss drugmaker loses patent...

It's final: Tasigna in, Sprycel out in NICE guidelines

The National Institute for Health and Clinical Excellence has struck again. Despite two appeals of its draft recommendations, the agency let in only one new drug for chronic myeloid leukemia.

NICE says nay to Sprycel, yea to discounted Tasigna

The U.K.'s cost-effectiveness watchdog rejected Bristol-Myers Squibb's ($BMY) Sprycel for chronic myeloid leukemia, but accepted Novartis' ($NVS) Glivec and its follow-up drug Tasigna after the Swiss

Novartis discount sways NICE toward Tasigna

The National Institute for Health and Clinical Excellence has taken Novartis ($NVS) up on its offer of a discount on Tasigna. The cost-effectiveness watchdog gave Tasigna a preliminary thumbs-up as a

Novartis, Pfizer see cancer data questioned

With cancer drugs, the first approval is only the beginning. An indication for one type of cancer can become two or three if drugmakers play their cards right--and if the treatments themselves prove

Novartis: Tasigna surpasses Glivec in study

Tasigna continues to surpass Glivec as a treatment for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, according to a statement issued

Tasigna gets Swiss nod as first-line drug

Novartis' Tasigna won its first European approval as a first-line treatment when Swiss authorities green-lighted the blood cancer drug after a fast-track review. Novartis release | Report

FDA slaps Novartis for Facebook widget

More evidence that social media is a potential minefield for drugmakers, at least until FDA finally makes up new rules. The agency's DDMAC division has cited Novartis for a Facebook widget on its

Novartis wins FDA nod for broader Tasigna use

Novartis has taken one step closer to making its cancer drug Tasigna a robust successor to its blockbuster treatment Gleevec. The FDA gave its blessing to Tasigna as a first-line treatment for a rare

Data aids Novartis push to replace Gleevec with Tasigna

What does a drugmaker do when a huge drug is edging toward that patent cliff? It pushes another branded med as a replacement for that soon-to-go-generic treatment--and crosses its fingers in hopes